InvestorsHub Logo
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

Re: None

Sunday, 04/11/2021 12:44:00 AM

Sunday, April 11, 2021 12:44:00 AM

Post# of 118382
According to the company, initial indications for NR2F6 activators include rheumatoid arthritis, inflammatory bowel disease and psoriasis, while indications for blockers include bladder cancer, myelodysplastic syndrome (a group of disorders caused by blood cells not formed or not working properly), and lung cancer.

Additional potential indications are solid tumors, acute leukemia and chronic graft-versus-host disease, which consists in the attack of the host’s cells by transplanted stem cells.

https://lupusnewstoday.com/2018/08/31/molecules-targeting-immune-protein-nr2f6-eyed-as-therapy-lupus/